This is a multicenter, randomized, double-blind, placebo-controlled phase II study designed to explore the efficacy and safety of different doses of SAL0140 in primary aldosteronism.
Aged ≥18 years , regardless of gender.
Diagnosed with primary aldosteronism (PA).
Mean seated office systolic blood pressure (msSBP) ≥145 mmHg.
Receiving stable background antihypertensive therapy.
Mean seated office systolic blood pressure (msSBP) ≥180 mmHg and/or mean seated office diastolic blood pressure (msDBP) ≥110 mmHg.
History or diagnosis of malignant hypertension, hypertensive emergency, hypertensive crisis or hypertensive encephalopathy.
History or diagnostic evidence of other secondary hypertension.
Prior surgical resection for adrenal adenoma.